방사성의약품
신흥
표적 분자에 방사성 동위원소를 실어 진단과 치료를 동시에 하는 방사성의약품(테라노스틱스).
전망 가장 뜨거운 분야 중 하나 — 대형 제약사 M&A가 활발. 알파 방출체와 새 표적 리간드가 성장 동력.
개발 기업
최신 연구
전체 →Science advances
알부민 결합에 의한 (177)Lu 표지 HER2 Fab 방사성 결합체의 약동학 및 치료 효과 개선Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Clinical Impact and Dynamics of Clonal Hematopoiesis with (177)Lu-PSMA-617 Therapy in Advanced Prostate CancerScientific reports
Assessment of potential nephrotoxicity biomarkers after [(177)Lu]Lu-DOTA-(Tyr(3))-octreotate administration and effects of antioxidant α(1)-microglobulinEuropean journal of nuclear medicine and molecular imaging
Predicting tumour and organ dose in α-radiopharmaceutical therapy: a (89)Zr-based dosimetric approach for (225)AcEndocrine connections
Systemic Management of Adrenal Malignancies: Adrenocortical carcinoma and pheochromocytoma/paragangliomaMolecular pharmaceutics
Evaluation of (161)Tb-Labeled DOTA-Ibandronate for Targeted Radionuclide Therapy in Bone MetastasesMolecular pharmaceutics
Radiolabeled Mesoporous Silica Nanosystem Enables Long-Term Cell Tracking In VivoMultiple sclerosis and related disorders
Retinal neuroaxonal degeneration in NMOSD vs. MS and unaffected controls: A systematic review and meta-analysis of OCT biomarkersJournal of medical Internet research
AI-Designed Radiopharmaceuticals: How Machine Learning Is Redefining Precision Cancer TherapyInternational journal of nanomedicine
Recent Advances and Future Perspectives on Chitosan-Sago-Derived Sodium Starch Glycolate as a Biopolymeric Carrier for Alpha-Mangostin Nanoparticles in Wound HealingBMJ oncology
Future of radiotheranosticsBrain communications
Neuroplasticity and immune system are related to altered grey matter networks: a cohort study in sporadic Alzheimer's disease
진행 중 임상
전체 →- 3상모집 예정Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
- 2상모집 중68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)
- 2상모집 예정Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary
- 1상모집 중177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
- 2상모집 중Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma
- 1상모집 중A Study of 177Lu-PSMA-617 in People With Gliomas
- 1상모집 중Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)
- 2상모집 중단 (진행 중)177LuPSMA in Renal Cell Carcinoma
- 1상모집 중Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617
- 3상모집 중Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
- 1상모집 중단 (진행 중)The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.
- 2상모집 중Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.